August 30, 2019

Trial of Cutaneous T-cell Lymphoma Therapy WP1220 Fully Enrolled

News

A Phase 2 clinical trial of WP1220, a potential topical treatment of cutaneous T-cell lymphoma (CTCL) lesions, has reached full patient enrollment. Developed by Moleculin Biotech, WP1220 is an inhibitor ... Read more

April 9, 2019

First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220

News

The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and ... Read more